Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Posted on 15 November 2018 | Posted by John Chapman | Posted in Videos, American Heart Association Scientific Sessions 2018

Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).

Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

Latest videos

PlayLDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
John Chapman LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
PlayWhy should clinical practice move to an intensive LDL-C lowering approach?
Chris Packard Why should clinical practice move to an intensive LDL-C lowering approach?
PlayHow do clinicians translate intensive LDL-C lowering to their practice?
Chris Packard How do clinicians translate intensive LDL-C lowering to their practice?
PlayAre very low lipoprotein(a) levels safe? Insights from the Copenhagen General Population Study
Are very low lipoprotein(a) levels safe? Insights from the Copenhagen General Population Study

« Back to videos